Market closed
Cara Therapeutics/$CARA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cara Therapeutics
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Ticker
$CARA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
10
Website
CARA Metrics
BasicAdvanced
$25M
-
-$15.53
0.50
-
Price and volume
Market cap
$25M
Beta
0.5
52-week high
$6.36
52-week low
$4.15
Average daily volume
16K
Financial strength
Current ratio
11.034
Quick ratio
10.674
Long term debt to equity
-967.734
Total debt to equity
-967.734
Interest coverage (TTM)
-6.58%
Management effectiveness
Return on assets (TTM)
-41.09%
Return on equity (TTM)
-270.01%
Valuation
Price to revenue (TTM)
3.548
Price to book
-5.52
Price to tangible book (TTM)
-5.52
Price to free cash flow (TTM)
-0.409
Growth
Revenue change (TTM)
-65.96%
Earnings per share change (TTM)
-40.86%
3-year revenue growth (CAGR)
-32.33%
3-year earnings per share growth (CAGR)
-9.46%
CARA News
AllArticlesVideos
Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics
GlobeNewsWire·1 day ago
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cara Therapeutics stock?
Cara Therapeutics (CARA) has a market cap of $25M as of April 15, 2025.
What is the P/E ratio for Cara Therapeutics stock?
The price to earnings (P/E) ratio for Cara Therapeutics (CARA) stock is 0 as of April 15, 2025.
Does Cara Therapeutics stock pay dividends?
No, Cara Therapeutics (CARA) stock does not pay dividends to its shareholders as of April 15, 2025.
When is the next Cara Therapeutics dividend payment date?
Cara Therapeutics (CARA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cara Therapeutics?
Cara Therapeutics (CARA) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.